Charles River Laboratories International, Inc.
CRL
$291.76
$9.423.34%
NYSE
| 06/27/2026 | 03/28/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 0.83% | 0.16% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 0.83% | 0.16% | |||
| Cost of Revenue | -7.09% | 1.12% | |||
| Gross Profit | 17.33% | -1.77% | |||
| SG&A Expenses | 43.63% | -22.34% | |||
| Depreciation & Amortization | -14.70% | -83.32% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 1.80% | -11.81% | |||
| Operating Income | -4.31% | 253.71% | |||
| Income Before Tax | 277.58% | 89.82% | |||
| Income Tax Expenses | 456.21% | 14.99% | |||
| Earnings from Continuing Operations | 94.87% | 94.64% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -1,660.98% | 84.53% | |||
| Net Income | 90.02% | 94.63% | |||
| EBIT | -4.31% | 253.71% | |||
| EBITDA | -3.63% | 33.09% | |||
| EPS Basic | 89.81% | 94.60% | |||
| Normalized Basic EPS | 1,655.31% | -75.26% | |||
| EPS Diluted | 89.81% | 94.60% | |||
| Normalized Diluted EPS | 1,655.31% | -75.26% | |||
| Average Basic Shares Outstanding | -1.90% | -0.54% | |||
| Average Diluted Shares Outstanding | -1.90% | -0.54% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||